Zhejiang Shenghua Biok Biology Co Ltd (600226) fair value: what the stock is really worth
As of Oct 22, 2026: fair value (intrinsic value) of Zhejiang Shenghua Biok Biology Co Ltd stock ¥0.87, price ¥4.38, upside -80.1%, quality 49 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 22, 2026.
How to read this chart
60‑month range ¥1.82 – ¥11.41 · fair‑value band ¥0.4300 – ¥0.9200 · the ¥4.38 price screens above the ¥0.8700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 22, 2026.
Follow Zhejiang Shenghua Biok Biology Co in your weekly email
Every Wednesday you see whether Zhejiang Shenghua Biok Biology Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zhejiang Hengtong Holding Co.,Ltd. develops, produces, and sells biological pesticides, veterinary drugs, and animal feed additive products in China and Internationally.
Show moreShow less
The company offers electronic and lithium battery copper foil for use in integrated circuit boards, lithium battery electrodes, and other products, as well as amino acid products.
It also engages in the cogeneration of heat and power and central heating, which includes electricity and steam; office and game software development; investment management; and film and television businesses. The company was incorporated in 1999 and is based in Huzhou, China.
Stock analysis
Zhejiang Shenghua Biok Biology Co Ltd (600226) currently trades at ¥4.38, while our model-based Fair Value estimate is ¥0.8700, 80.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥1.08 per share, and 0 of the 9 models we run sit above the ¥4.38 price.
Bear case: the Asset-Based group reads lowest at ¥0.1400, and 9 of the 9 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥0.4300 (bear) to ¥0.9200 (bull), the price of ¥4.38 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Industrials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Zhejiang Shenghua Biok Biology Co Ltd reported revenue of 1.3B CNY in FY2024 versus 556M CNY in FY2020, a compound +24.5%/yr. Reported net income was 189M CNY in FY2024.
Key figures
Market cap 13.0B CNY (≈ $2.0B) Small · P/E ratio 73.0 · P/S ratio 5.34 · EPS (TTM) ¥0.0600 · Dividend yield 0.1% · Net margin 6.8% · Return on equity 4.6% · Return on assets (EBIT) 1.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (medium confidence).
What moves the price
The share trades about 62% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at 6% fair-value upside, at −80%, 600226 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.0600 to ¥3.42). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear¥0.4300Fair Value ¥0.8700Bull¥0.9200
Price ¥4.38 · Upside -80.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2024 figures (about 12 months old). Earnings retained since then (¥0.0600 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.42/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+106.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.6%
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.8%
’13
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+3.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.7%
Dividend (yield on the price)0.1%
Per share before 2002divided by the spin-off factor 1.0404
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3.7% vs 3.2%, steady
⚠ Revenue per share shrinking 15.5%/yr over ~10Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Zhejiang Shenghua Biok Biology Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Conglomerates · 353 stocks
Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score49 · Below median
Fair Value upside−80.1% · Bottom 25%
Profitability
Return on equity (12 months)4.6% · Below median
Return on assets4.2% · Above median
Net margin (12 months)6.8% · Above median
Operating margin (12 months)2.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)63.7% · Top 25%
Dividend yield (12 months)0.1% · Bottom 25%
Balance sheet
Debt / equity0.09× · Below median
Valuation Multiplesvs Conglomerates median · lower = cheaper
P/E (12 months)73.0× · Priciest 25%
P/B3.81× · Priciest 25%
P/S (12 months)5.34× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 48
FUTURE (revenue growth)100· sector 36
PAST (return on equity)18· sector 21
HEALTH (low debt)95· sector 90
DIVIDEND (yield)2· sector 45
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Zhejiang Shenghua Biok Biology Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/600226
Frequently asked questions
Is Zhejiang Shenghua Biok Biology Co Ltd (600226) overvalued or undervalued?
As of Oct 22, 2026, our model estimates a fair value of ¥0.8700 versus a price of ¥4.38, about −80% upside (overvalued).
What is the fair value of 600226?
Our model-based fair value for Zhejiang Shenghua Biok Biology Co Ltd is ¥0.8700 (as of Oct 22, 2026), built from audited fundamentals. The current price: ¥4.38.
What is the quality score of 600226?
Zhejiang Shenghua Biok Biology Co Ltd has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhejiang Shenghua Biok Biology Co Ltd (600226)?
Our model-based price target is the fair value of ¥0.8700 (as of Oct 22, 2026) from 9 valuation models. Cautious scenario ¥0.4300, optimistic scenario ¥0.9200. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhejiang Shenghua Biok Biology Co Ltd stock forecast for 2026?
Our models put fair value at ¥0.8700, about −80% upside versus a price of ¥4.38 (overvalued). Cautious scenario ¥0.4300, optimistic scenario ¥0.9200. The calculation is refreshed regularly with new filings.
What is the revenue of Zhejiang Shenghua Biok Biology Co Ltd (600226)?
Zhejiang Shenghua Biok Biology Co Ltd reported trailing-twelve-month revenue of about 2.4B CNY (latest available figure, as of Oct 22, 2026).
Does Zhejiang Shenghua Biok Biology Co Ltd pay a dividend?
Zhejiang Shenghua Biok Biology Co Ltd currently shows a dividend yield of 0.09% relative to its recent price (as of Oct 22, 2026).
What is the intrinsic value of Zhejiang Shenghua Biok Biology Co Ltd (600226)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhejiang Shenghua Biok Biology Co Ltd it is ¥0.8700 per share (as of Oct 22, 2026), against a price of ¥4.38. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Zhejiang Shenghua Biok Biology Co Ltd stock overvalued or undervalued in 2026?
As of Oct 22, 2026, 600226 trades above its calculated fair value: price ¥4.38, fair value ¥0.8700, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 600226?
No. The price is what the market pays today (¥4.38); the fair value is what the company's own numbers justify (¥0.8700). For Zhejiang Shenghua Biok Biology Co Ltd the two are ¥3.51 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhejiang Shenghua Biok Biology Co Ltd worth?
The market values Zhejiang Shenghua Biok Biology Co Ltd at about 13.0B CNY (market capitalisation, as of Oct 22, 2026). Per share that is ¥4.38; our models calculate a fair value of ¥0.8700 per share.
What do the bullish and bearish scenarios say about 600226?
Our models span a range for Zhejiang Shenghua Biok Biology Co Ltd: cautious scenario ¥0.4300, base ¥0.8700, optimistic ¥0.9200 per share (as of Oct 22, 2026, price ¥4.38). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 600226?
Zhejiang Shenghua Biok Biology Co Ltd trades at a price-to-earnings ratio of 73.0 (as of Oct 22, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥0.8700 is built from several models across several years. Other multiples: P/B 3.8, P/S 5.3.
How solid is the balance sheet of Zhejiang Shenghua Biok Biology Co Ltd (600226)?
Balance-sheet figures for Zhejiang Shenghua Biok Biology Co Ltd (as of Oct 22, 2026): return on equity 4.6%, debt of 0.09 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 600226 from its 52-week high?
Zhejiang Shenghua Biok Biology Co Ltd trades at ¥4.38, about 62% below its 52-week high of ¥11.41 and 7% above the low of ¥4.08 (as of Oct 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.8700 is for.
Which stocks are comparable to Zhejiang Shenghua Biok Biology Co Ltd?
From the same area (Industrials) we also value 3M Company, Honeywell International Inc, Swire Pacific Limited, SGH Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhejiang Shenghua Biok Biology Co Ltd stock attractive at the current price?
The data as of Oct 22, 2026: price ¥4.38, calculated fair value ¥0.8700 (−80%), Quality Score 49/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 600226 calculated?
We run Zhejiang Shenghua Biok Biology Co Ltd through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥0.8700, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Zhejiang Shenghua Biok Biology Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhejiang Shenghua Biok Biology Co Ltd (600226)?
The closing price on Oct 22, 2026 was ¥4.38. Our model-based fair value is ¥0.8700, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhejiang Shenghua Biok Biology Co Ltd right now?
The price sits above even our optimistic bull case (¥0.9200). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥0.4300 to ¥0.9200) leaves room in how you read the outcome.
Where does the earnings growth of Zhejiang Shenghua Biok Biology Co Ltd (600226) come from?
Earnings per share at Zhejiang Shenghua Biok Biology Co Ltd grew +7.5 % a year from 2013 to 2024. Broken into its drivers: revenue per share −10.4 %, EBIT margin +22.3 %, tax rate −0.9 %, residual (interest, one-offs) −1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Zhejiang Shenghua Biok Biology Co Ltd
How large is the market capitalisation of Zhejiang Shenghua Biok Biology Co Ltd (600226)?
The market capitalisation of Zhejiang Shenghua Biok Biology Co Ltd is 13.0B CNY (≈ $2.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhejiang Shenghua Biok Biology Co Ltd (600226)?
The price-to-sales ratio of Zhejiang Shenghua Biok Biology Co Ltd is 5.34 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhejiang Shenghua Biok Biology Co Ltd (600226)?
Earnings per share at Zhejiang Shenghua Biok Biology Co Ltd are ¥0.0600 (price ÷ EPS = P/E 73.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zhejiang Shenghua Biok Biology Co Ltd (600226)?
The dividend yield of Zhejiang Shenghua Biok Biology Co Ltd is 0.1% (payout 6.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zhejiang Shenghua Biok Biology Co Ltd (600226)?
The net margin of Zhejiang Shenghua Biok Biology Co Ltd is 6.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhejiang Shenghua Biok Biology Co Ltd (600226)?
The return on equity (ROE) of Zhejiang Shenghua Biok Biology Co Ltd is 4.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhejiang Shenghua Biok Biology Co Ltd (600226)?
On an EBIT basis the return on assets of Zhejiang Shenghua Biok Biology Co Ltd is 1.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhejiang Shenghua Biok Biology Co Ltd (600226)?
The operating margin of Zhejiang Shenghua Biok Biology Co Ltd is 2.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhejiang Shenghua Biok Biology Co Ltd (600226)?
Revenue at Zhejiang Shenghua Biok Biology Co Ltd is growing +63.7% versus a year earlier (3y avg +25.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zhejiang Shenghua Biok Biology Co Ltd (600226)?
Earnings per share at Zhejiang Shenghua Biok Biology Co Ltd are growing −60.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zhejiang Shenghua Biok Biology Co Ltd (600226) generate?
The free cash flow of Zhejiang Shenghua Biok Biology Co Ltd is −163M CNY (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Zhejiang Shenghua Biok Biology Co Ltd (600226) hold?
Zhejiang Shenghua Biok Biology Co Ltd holds more cash than debt, 248M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Zhejiang Shenghua Biok Biology Co Ltd in the live analysis
One click puts Zhejiang Shenghua Biok Biology Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 22, 2026